I agree that 'breakthrough' is a premature description if the reader thinks that it applies to pre-clinical drugs targeting pancreatic and gallbladder cancers.
I respectfully suggest, however, that the breakthrough in this case refers to the ability to retard the Phase 2 metabolism process.
- Forums
- ASX - By Stock
- NOX
- Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline
Ann: Pre-Clinical Breakthrough Discovery Set to Expand Pipeline, page-10
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
|
|||||
Last
6.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $20.16M |
Open | High | Low | Value | Volume |
7.2¢ | 7.2¢ | 6.9¢ | $591 | 8.493K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 60978 | 6.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 47310 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 60978 | 0.069 |
2 | 14000 | 0.068 |
2 | 47278 | 0.066 |
1 | 15000 | 0.065 |
1 | 79000 | 0.063 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 47310 | 2 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
0.080 | 100000 | 1 |
Last trade - 15.07pm 30/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online